Last reviewed · How we verify
Fluticasone 0.005%
Fluticasone 0.005% is a Topical corticosteroid Small molecule drug developed by Astellas Pharma Inc. It is currently FDA-approved for Inflammatory skin conditions (e.g., eczema, dermatitis, psoriasis), Pruritus and other dermatological inflammatory disorders. Also known as: Flixovate® 0.005%.
Fluticasone is a corticosteroid that suppresses local immune and inflammatory responses by binding to glucocorticoid receptors.
Fluticasone 0.005% is a small molecule glucocorticoid receptor agonist, classified as an agonist. It has been studied for various conditions including atopic dermatitis, skin inflammation, and allergic conjunctivitis.
At a glance
| Generic name | Fluticasone 0.005% |
|---|---|
| Also known as | Flixovate® 0.005% |
| Sponsor | Astellas Pharma Inc |
| Drug class | Topical corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Fluticasone propionate is a potent topical corticosteroid that reduces inflammation, itching, and other dermatological symptoms by activating glucocorticoid receptors in skin and mucosal tissues. At 0.005% concentration, it is typically formulated for topical application to treat inflammatory skin conditions. The drug works by inhibiting the release of inflammatory mediators and reducing immune cell infiltration at the site of application.
Approved indications
- Inflammatory skin conditions (e.g., eczema, dermatitis, psoriasis)
- Pruritus and other dermatological inflammatory disorders
Common side effects
- Local skin atrophy
- Burning or stinging at application site
- Folliculitis
- Hypopigmentation
Key clinical trials
- Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation (PHASE2, PHASE3)
- Randomized Study to Compare the Bioavailability of Two Fluticasone Propionate 0.005% Topical Ointments
- Efficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CAC™ Model (PHASE2)
- Protopic Ointment in Adult Atopic Eczema of the Face (PHASE4)
- Protopic Ointment in Children Atopic Eczema (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluticasone 0.005% CI brief — competitive landscape report
- Fluticasone 0.005% updates RSS · CI watch RSS
- Astellas Pharma Inc portfolio CI
Frequently asked questions about Fluticasone 0.005%
What is Fluticasone 0.005%?
How does Fluticasone 0.005% work?
What is Fluticasone 0.005% used for?
Who makes Fluticasone 0.005%?
Is Fluticasone 0.005% also known as anything else?
What drug class is Fluticasone 0.005% in?
What development phase is Fluticasone 0.005% in?
What are the side effects of Fluticasone 0.005%?
What does Fluticasone 0.005% target?
Related
- Drug class: All Topical corticosteroid drugs
- Target: All drugs targeting Glucocorticoid receptor
- Manufacturer: Astellas Pharma Inc — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Inflammatory skin conditions (e.g., eczema, dermatitis, psoriasis)
- Indication: Drugs for Pruritus and other dermatological inflammatory disorders
- Also known as: Flixovate® 0.005%
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing